Measles natural history, complications and prognosis: Difference between revisions
Created page with "{{Measles}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Pediatrics Category:Infectious disease Category:Dermatology {{WH}} ..." |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
==Complications== | |||
Complications with measles are relatively common, ranging from relatively mild and less serious [[diarrhea]], to [[pneumonia]] and [[encephalitis]] ([[subacute sclerosing panencephalitis]]). Complications are usually more severe amongst adults who catch the virus. | |||
The [[fatality rate]] from measles for otherwise healthy people in developed countries is low: approximately 1 death per thousand cases. In underdeveloped nations with high rates of [[malnutrition]] and poor [[healthcare]], fatality rates of 10 percent are common. In [[immunocompromised]] patients, the fatality rate is approximately 30 percent. | |||
==References== | ==References== | ||
Revision as of 20:54, 8 February 2012
|
Measles Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Measles natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Measles natural history, complications and prognosis |
|
Measles natural history, complications and prognosis in the news |
|
Blogs on Measles natural history, complications and prognosis |
|
Risk calculators and risk factors for Measles natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Complications
Complications with measles are relatively common, ranging from relatively mild and less serious diarrhea, to pneumonia and encephalitis (subacute sclerosing panencephalitis). Complications are usually more severe amongst adults who catch the virus.
The fatality rate from measles for otherwise healthy people in developed countries is low: approximately 1 death per thousand cases. In underdeveloped nations with high rates of malnutrition and poor healthcare, fatality rates of 10 percent are common. In immunocompromised patients, the fatality rate is approximately 30 percent.